2026-10-13T18:43:35Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33980893 2026-09-24T09:21:12Z category_7 portal_147 item_type_3 month_year_09_2026

Supplemental Material for: Efficacy of adjuvant nivolumab versus adjuvant gemcitabine plus cisplatin/carboplatin after radical nephroureterectomy for upper tract urothelial carcinoma: a real-world analysis using a Japanese large-scale claims database figshare admin karger (2628495) Akihito Hashizume (25103183) Kawahara, Takashi (22575569) Masanobu Yamazaki (25103188) Daiki Ueno (15012105) Shinnosuke Kuroda (4849705) Teppei Takeshima (8456343) Daiji Takamoto (25103191) Takeaki Noguchi (25103194) Yasushi Yumura (5940665) Hiroji Uemura (294173) Kazuhide Makiyama (4849708) Jun-ichi Teranishi (301378) Medicine Medicine <p dir="ltr">Introduction: Upper tract urothelial carcinoma (UTUC) is a relatively rare malignancy with a poor prognosis. Although adjuvant platinum-based chemotherapy is a standard treatment after radical nephroureterectomy (RNU), the efficacy of adjuvant nivolumab in UTUC remains unclear, especially in real clinical practice. We examined this using a large Japanese real-world database.</p><p dir="ltr">Methods: Using the Medical Data Vision database, we identified UTUC patients who underwent RNU and received adjuvant therapy. The adjuvant GC/GCarbo group and the adjuvant nivolumab group were defined by distinct treatment eras to reduce treatment selection bias. Event-free survival (EFS) was compared using Kaplan-Meier curves and the log-rank test, with a sensitivity analysis truncating follow-up at 300 days.</p><p dir="ltr">Results: A total of 1,058 patients were analyzed (240 nivolumab, 818 GC/GCarbo). In the whole cohort, EFS was significantly longer in the nivolumab group (HR = 0.6365, P = 0.0076). This association was consistent in patients with neoadjuvant chemotherapy (HR = 0.4053, P = 0.001) and in those without it (HR = 0.6765, P = 0.0462).</p><p dir="ltr">Conclusion: In Japanese UTUC patients, adjuvant nivolumab was associated with a longer event-free survival than GC/GCarbo. Because this was an unadjusted, observational comparison, the finding should be interpreted with caution and regarded as hypothesis-generating.</p> 2026-09-24T09:21:12Z Dataset Dataset 10.6084/m9.figshare.33980893.v1 https://figshare.com/articles/dataset/Supplemental_Material_for_Efficacy_of_adjuvant_nivolumab_versus_adjuvant_gemcitabine_plus_cisplatin_carboplatin_after_radical_nephroureterectomy_for_upper_tract_urothelial_carcinoma_a_real-world_analysis_using_a_Japanese_large-scale_claims_/33980893 CC BY 4.0